Metabolic Risk Factors and Myocardial Oxygenation Reserve ((META-MORE))
Metabolic Risk Factors and Myocardial Oxygenation Reserve (META-MORE)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Katherine Lindsay, Master
- Phone Number: 37305 514-934-1934
- Email: katherine.lindsay@mail.mcgill.ca
Study Contact Backup
- Name: Elizabeth Konidis, Master
- Phone Number: 37305 514-934-1934
- Email: elisavet.konidis@muhc.mcgill.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4A 3J1
- Recruiting
- The Reseach Institute of the McGill University Health Centre
-
Contact:
- Katherine Lindsay, Master
- Phone Number: 37305 514-9341934
- Email: katherine.lindsay@mail.mcgill.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patient Participants:
- Age 18-80
- Informed Consent
- Diagnosis of MetS (through at least 3 MetS characteristics (abdominal obesity, high triglyceride level, low HDL cholesterol, high systolic blood pressure, and high fasting glucose levels)
Healthy Volunteers:
- Age 18-80
- No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system
- No Smoking
Exclusion Criteria:
- General MRI contraindications*
- Pacemakers, defibrillating wires, implanted defibrillators, intracranial aneurysm clips, metallic foreign bodies in the eyes, knowledge or suspicion of pregnancy.
- Consumption of caffeine (coffee, tea, cocoa, chocolate, "energy drink") during the 12 hours prior to the exam
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patient Participant
Participants with known Metabolic Syndrome (MetS)
|
Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
Other Names:
|
|
Healthy Volunteers
NonS-moking participants with no known pre-existing conditions and who do not take any medications
|
Participants will undergo an oxygenation-sensitive cardiac MRI and, during the scan, perform a vasoactive breathing maneuver composed of a period of paced hyperventilation followed by a voluntary maximal breath hold.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global and segmental Myocardial oxygenation reserve (MORE)
Time Frame: Baseline
|
A t-test will be used to assess the difference in global and segmental MORE, at rest, during hyperventilation, and throughout breath hold, between healthy and volunteers and MetS patients.
|
Baseline
|
|
Relation between Breathing maneuver induced MORE and known MetS risk factors.
Time Frame: Baseline
|
A linear regression will assess the relation between Breathing maneuver induced MORE and known MetS risk factors, biomarkers, and time since diagnosis.
|
Baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2021-7267
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.